“…In a recent study published in The New England Journal of Medicine, researchers theorized that a monoclonal antibody that neutralizes all SARS-CoV-2 would target a highly conserved epitope that would remain effective as SARS-CoV-2 mutates ( Aschenbrenner, 2021 ). In the phase III, multicenter, double-blind, placebo-controlled study, SARS-CoV-2 Monoclonal Antibody Efficacy Trial–Intent to Care Early (COMET-ICE), Researchers evaluated the impact of a single intravenous infusion of sotrovimab 500 mg on mild-to-moderate SARS-CoV-2 in high-risk, non-hospitalized patients ( Cheng et al., 2021 ). The risk of severe SARS-CoV-2 is higher in patients over 55 years old or in those who have diabetes, obesity, chronic kidney disease, chronic obstructive pulmonary disease, congestive heart failure, or moderate-to-severe asthma.…”